Phos enzyme ID'd using CRISPR may lead to safer cancer meds say researchers

By Gareth Macdonald contact

- Last updated on GMT

Inhibiting Fam20C enzyme in cancer cells my field new treatments
Inhibiting Fam20C enzyme in cancer cells my field new treatments

Related tags: Cancer

A newly identified enzyme that modifies secreted proteins could lead to safer cancer drugs and new osteoporosis treatments say scientists.

Phosphorylation - the addition of a phosphate group to a molecule - controls the activity of proteins produced inside cells. The extra phosphate group can - for example - activate or turn off an enzyme or guide a protein's migration.

Secreted proteins are also phosphorylated, however, until now little was known about the enzymes involved in the process.

This week​ researchers from the University of California, San Diego School of Medicine announced that a single enzyme - Fam20C - is responsible for the phosphorylation of more than 100 secreted proteins in a paper in the Journal Cell.

Raine syndrome

The lack of fully functional Fam20C results in bone deformities and the condition is usually fatal at birth.

Gene editing 

The team used CRISPR/Cas9 gene editing to delete the Fam20C gene from liver, breast and bone cancer cells and observed that proteins secreted by the modified cells were not phosphorylated. 

They finding could result in new oncology drugs because Fam20C is overexpressed by cancerous cells explained co-lead author Vincent Tagliabracci.

At first glance, it appears that Fam20C would not be a great target due to the wide variety of substrates that it phosphorylates. One would expect multiple off-target effects and would likely have a detrimental effect on biomineralization as seen in patients with Raine syndrome.​ 

However," ​Tagliabracci continued "specifically targeting a Fam20C inhibitor to tumors would likely reduce the off-target effects and may be beneficial in slowing cancer cell metastasis​."

Targeting the enzyme could also provide a new treatment option for patients with osteoporosis according to Tagliabracci who said: “A Fam20C activator targeted to bone would—theoretically—increase bone density and perhaps be efficacious for patients​.”

Tagliabracci told BioPharma-reporter.com the research has already attracted interest from the pharmaceutical industry.

Source: Cell

A Single Kinase Generates the Majority of the Secreted Phosphoproteome

DOI: http://dx.doi.org/10.1016/j.cell.2015.05.028

Related topics: Bio Developments, Cell lines

Related news

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars